Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU; Dietary Supplement
Lead sponsor: Texas A&M University; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions: Not listed
Lead sponsor: Global Healthy Living Foundation; Other
Eligibility: 19 Years and older
Enrollment: 40,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Upper Nyack, New York

Conditions: Asthma, Communication
Interventions: Portal training and home visits, Portal training; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Lymphocytic Leukemia
Interventions: Oblimersen-rituximab-fludarabine; Drug
Lead sponsor: Genta Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2010
U.S. locations: 3
States / cities: Washington D.C., District of Columbia • Buffalo, New York • New Hyde Park, New York

Conditions: Asthma
Interventions: Anti-Asthma Herbal Medical Intervention (ASHMI); Drug
Lead sponsor: Xiu-Min Li; Other
Eligibility: 18 Years to 55 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer, Liver Cirrhosis, Chronic Hepatitis, Hepatitis B, Hepatitis C, Diabetes, COPD
Interventions: Multi-analyte Blood Test; Diagnostic Test
Lead sponsor: Helio Genomics; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Timeline: 2019 – 2028
U.S. locations: 7
States / cities: Redondo Beach, California • Coon Rapids, Minnesota • Fridley, Minnesota + 4 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: Respimat inhaler, tiotropium+olodaterol (low dose), tiotropium + olodaterol (high dose), placebo to tiotropium+olodaterol; Device · Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 404 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 15
States / cities: Torrance, California • Hartford, Connecticut • Springfield, Illinois + 12 more

Conditions: Asthma, Wheezing, Immunosuppression
Interventions: No Intervention; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: Not listed
Enrollment: 321,697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Allergy, Asthma
Interventions: Glycerinated German cockroach allergenic extract, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 5 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: simvastatin, Placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 40 Years to 80 Years
Enrollment: 885 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 35
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 26 more

Conditions: Asthma
Interventions: QAX576, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Phoenix, Arizona • Huntington Beach, California • Owensboro, Kentucky + 7 more

Conditions: Asthma
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Asthma
Interventions: ENV-294, Placebo; Drug
Lead sponsor: Enveda Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Jose, California + 11 more

Conditions: Pulmonary Hypertension, COPD
Interventions: Inhaled Treprostinil Therapy; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 2
States / cities: Aurora, Colorado • Jacksonville, Florida

Conditions: Pneumonia, Bronchiolitis, Asthma Exacerbation, Croup, Reactive Airway Disease, Upper Respiratory Disease, Viral Lower Respiratory Tract Infections, Lower Respiratory Disease
Interventions: Recordings of Infants and Children's Cough Sounds; Device
Lead sponsor: ResApp Health Limited; Industry
Eligibility: 29 Days to 12 Years
Enrollment: 1,470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Boston, Massachusetts • Cleveland, Ohio • Houston, Texas

Conditions: Asthma
Interventions: Tozorakimab, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 63
States / cities: Bakersfield, California • Huntington Beach, California • La Mesa, California + 59 more

Conditions: HIV, Asthma
Interventions: Darunavir, Ritonavir, Beclomethasone Dipropionate HFA; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: Albuterol, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years to 11 Years
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 14
States / cities: Little Rock, Arkansas • Huntington Beach, California • San Jose, California + 11 more

Conditions: Chronic Obstructive Pulmonary Disease - COPD
Interventions: Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Placebo for formoterol fumarate, Formoterol fumarate (12 μg), Formoterol fumarate (40 μg); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years to 130 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Glendale, Arizona • Phoenix, Arizona • Tempe, Arizona + 17 more

Conditions: Asthma
Interventions: Xolair; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 45 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Homogeneous Emphysema
Interventions: Biologic Lung Volume Reduction; Biological
Lead sponsor: Aeris Therapeutics; Industry
Eligibility: 40 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 8
States / cities: Birmingham, Alabama • Phoenix, Arizona • Iowa City, Iowa + 5 more

Conditions: COPD
Interventions: Bipap (Respironics, Inc); Device
Lead sponsor: University of Iowa; Other
Eligibility: 35 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Albuterol Spiromax®; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 4 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 30
States / cities: Phoenix, Arizona • Costa Mesa, California • Huntington Beach, California + 27 more

Conditions: Asthma
Interventions: Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo; Drug
Lead sponsor: West-Ward Pharmaceutical; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 1,556 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Search by objective public record fields.

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

PatientSpot Formerly Known as ArthritisPower

Using IT to Improve Access, Communication and Asthma in African American and Hispanic/Latino Adults

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

Safety Study of Chinese Herbal Therapy to Treat Asthma

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children

Sublingual Cockroach Safety in Adults With Cockroach Allergy & Perennial Allergic Rhinitis With or Without Asthma

Simvastatin Therapy for Moderate and Severe COPD

Efficacy of QAX576 in Asthma

Characterizing Asthma Sputum Elasticity in the UCSF Severe Asthma Research Program

ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults

Treatment of Pulmonary Hypertension Associated COPD With Inhaled Treprostinil-1

Diagnosing Respiratory Disease in Children Using Cough Sounds 2

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers

Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)

Immune Dysfunction in Allergic Asthma

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Trial of Non-invasive Ventilation for Stable COPD

Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)